Recombinant Vaccines Market Size, Share, Growth 2023-2031
Recombinant Vaccines Market Size, Share, Growth 2023-2031
Recombinant vaccines are those that contain a DNA sequence encoding the antigen(s) against which an immune response is targeted

According to the report by Expert Market Research (EMR), the global recombinant vaccines market size attained a value of USD 13.32 billion in 2022. Aided by the rising prevalence of infectious diseases and the expanding applications of recombinant vaccines in the healthcare sector, the market is anticipated to grow at a CAGR of 11.91% during the forecast period of 2023-2031 to attain a value of USD 36.62 billion by 2031.

Recombinant vaccines are those that contain a DNA sequence encoding the antigen(s) against which an immune response is targeted. They were created utilising recombinant DNA technology. These vaccines are used to prevent and treat a number of illnesses, such as meningococcal disease, hepatitis B, and HPV. Recombinant vaccines are valuable components in the field of immunisation because they are well-tolerated, safe, and elicit a strong immune response in addition to their preventative qualities.

The growing global burden of infectious diseases is driving the global recombinant vaccines market growth. With the increasing awareness of the benefits associated with vaccination, there has been a significant shift towards widespread immunisation, leading to a surge in demand for recombinant vaccines. Moreover, the recent pandemic has further highlighted the critical role of vaccines in global health, leading to increased investments and focus on vaccine development.

Get a Free Sample Report with Table of Contents –

The expanding applications of recombinant vaccines in the healthcare industry significantly contribute to the recombinant vaccines market development. In the field of preventive healthcare, recombinant vaccines are used as a key tool in the control and eradication of numerous infectious diseases. Their application has been instrumental in the management of several high-burden diseases, thereby reducing morbidity and mortality rates.

Additionally, the rapid advancements in biotechnology and genetic engineering have led to the development of more sophisticated and targeted recombinant vaccines, opening up new avenues for recombinant vaccines market expansion. The increasing trend of personalised medicine also contributes to the rising popularity of recombinant vaccines as these offer the possibility of creating individualised vaccines based on a person’s genetic makeup.

Further, the growing demand for safe and effective vaccines in the healthcare industry has led to an increased focus on recombinant vaccines, thus increasing the recombinant vaccines market demand. With the rise of chronic diseases and the increasing geriatric population, there has been an increased emphasis on preventive healthcare, where recombinant vaccines play a critical role. As such, they are becoming an essential component in the formulation of immunisation programmes globally, thereby boosting the recombinant vaccines market expansion.

Recombinant Vaccines Market Segmentation

The market can be divided based on type, disease indication, distribution channel, end user, and region.

Read Full Report with Table of Contents –

Market Breakup by Type

• Live Attenuated
• Subunit

Market Breakup by Disease Indication

• Hepatitis B
• Rotavirus
• Herpes Zoster
• Meningococcal B
• Others

Market Breakup by Distribution Channel

• Hospitals
• Vaccination Centres

Market Breakup by End User

• Paediatrics
• Adults
• Veterinary

Market Breakup by Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Competitive Landscape

The EMR report looks into the market shares, plant turnarounds, capacities, investments, and acquisitions and mergers, among other major developments, of the global recombinant vaccines companies. Some of the major key players explored in the report by Expert Market Research are as follows:

• GSK plc
• Pfizer Inc.
• Sanofi
• Walvax Biotechnology Co., Ltd. (Walvax)
• Dynavax Technologies Corporation
• Merck & Co., Inc.
• Novartis AG
• GC Biopharma
• Bayer AG
• Bharat Biotech
• Sartorius AG
• Serum Institute of India Pvt. Ltd.
• Bio Farma

About Us:

Acquire unparalleled access to critical industry insights with our comprehensive market research reports, meticulously prepared by a team of seasoned experts. These reports are designed to equip decision-makers with an in-depth understanding of prevailing market trends, competitive landscapes, and growth opportunities.

Our high-quality, data-driven analyses provide the essential framework for organisations seeking to make informed and strategic decisions in an increasingly complex and rapidly evolving business environment. By investing in our market research reports, you can ensure your organisation remains agile, proactive, and poised for success in today’s competitive market.

Don’t miss the opportunity to elevate your business intelligence and fortify your strategic planning. Secure your organisation’s future success by acquiring one of our Expert Market Research reports today.

Media Contact:

Company Name: Claight Corporation
Contact Person: Joe Goldberg, Business Consultant
Toll-Free Number: US +1-415-325-5166 | UK +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA

What's your reaction?


0 comment

Write the first comment for this!

Facebook Conversations